These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 17192115)

  • 1. Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment.
    Donohue JM; Pincus HA
    Pharmacoeconomics; 2007; 25(1):7-24. PubMed ID: 17192115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the impact of enhanced depression treatment on workplace functioning and costs: a cost-benefit approach.
    Lo Sasso AT; Rost K; Beck A
    Med Care; 2006 Apr; 44(4):352-8. PubMed ID: 16565636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the Societal Benefits of THA After Accounting for Work Status and Productivity: A Markov Model Approach.
    Koenig L; Zhang Q; Austin MS; Demiralp B; Fehring TK; Feng C; Mather RC; Nguyen JT; Saavoss A; Springer BD; Yates AJ
    Clin Orthop Relat Res; 2016 Dec; 474(12):2645-2654. PubMed ID: 27699631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of integrated care for elderly depressed patients in the PRISM-E study.
    Wiley-Exley E; Domino ME; Maxwell J; Levkoff SE
    J Ment Health Policy Econ; 2009 Dec; 12(4):205-13. PubMed ID: 20195008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model.
    Botteman MF; Ozminkowski RJ; Wang S; Pashos CL; Schaefer K; Foley DJ
    CNS Drugs; 2007; 21(4):319-34. PubMed ID: 17381185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of interventions for depressed Latinos.
    Schoenbaum M; Miranda J; Sherbourne C; Duan N; Wells K
    J Ment Health Policy Econ; 2004 Jun; 7(2):69-76. PubMed ID: 15208467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
    Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
    J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economics of psychosocial factors in patients with cardiovascular disease.
    Rodwin BA; Spruill TM; Ladapo JA
    Prog Cardiovasc Dis; 2013; 55(6):563-73. PubMed ID: 23621966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic burden of depression and the cost-effectiveness of treatment.
    Wang PS; Simon G; Kessler RC
    Int J Methods Psychiatr Res; 2003; 12(1):22-33. PubMed ID: 12830307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of depression in Europe.
    Sobocki P; Jönsson B; Angst J; Rehnberg C
    J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of a psychoeducational relapse prevention program for depression in primary care.
    Stant AD; TenVergert EM; Kluiter H; Conradi HJ; Smit A; Ormel J
    J Ment Health Policy Econ; 2009 Dec; 12(4):195-204. PubMed ID: 20195007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of a guideline-based clinical pathway of care to improve health outcomes following whiplash injury (Whiplash ImPaCT): protocol of a randomised, controlled trial.
    Rebbeck T; Leaver A; Bandong AN; Kenardy J; Refshauge K; Connelly L; Cameron I; Mitchell G; Willcock S; Ritchie C; Jagnoor J; Sterling M
    J Physiother; 2016 Apr; 62(2):111. PubMed ID: 26996096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Humanistic, Societal, and Pharmaco-economic Burden of Angioedema.
    Longhurst H; Bygum A
    Clin Rev Allergy Immunol; 2016 Oct; 51(2):230-9. PubMed ID: 27388236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the health-related quality of life and economic impact of Parkinson's disease.
    Dowding CH; Shenton CL; Salek SS
    Drugs Aging; 2006; 23(9):693-721. PubMed ID: 17020395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic aspects of the association between diabetes and depression: a systematic review.
    Molosankwe I; Patel A; José Gagliardino J; Knapp M; McDaid D
    J Affect Disord; 2012 Oct; 142 Suppl():S42-55. PubMed ID: 23062857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Costs and Cost-effectiveness of Collaborative Care for Adolescents With Depression in Primary Care Settings: A Randomized Clinical Trial.
    Wright DR; Haaland WL; Ludman E; McCauley E; Lindenbaum J; Richardson LP
    JAMA Pediatr; 2016 Nov; 170(11):1048-1054. PubMed ID: 27654449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis.
    Boonen A; Mau W
    Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S112-7. PubMed ID: 19822056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.